medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2023-230medsovet-7734Research ArticleКОМОРБИДНЫЙ ПАЦИЕНТCOMORBID PATIENTПсихоэмоциональное состояние пациентов с хроническими неинфекционными заболеваниями: важные аспекты терапииPsycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapyhttps://orcid.org/0000-0002-1042-4275ШишковаВ. Н.ShishkovaV. N.

Шишкова Вероника Николаевна -доктор медицинских наук, ведущий научный сотрудник, руководитель отдела профилактики когнитивных и психоэмоциональных нарушений.

101000, Москва, Петроверигский пер., д. 10

Veronika N. Shishkova -Dr. Sci. (Med.), Leading Researcher, Head of the Department for the Prevention of Cognitive and Psychoemotional Events.

10, Petroverigskiy Lane, Moscow, 101990

veronika-1306@mail.ruНациональный медицинский исследовательский центр профилактической медициныРоссияNational Medical Research Center for Preventive MedicineRussian Federation202320082023013256262Copyright © Шишкова В.Н., 20232023Шишкова В.Н.Shishkova V.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7734

Психоэмоциональные нарушения, такие как депрессия и тревожные расстройства, являются важными модифицируемыми факторами риска развития и осложненного течения многих распространенных хронических неинфекционных заболеваний. Особенностью данной коморбидности является значимое влияние психоэмоциональных расстройств на мотивацию и приверженность пациентов к здоровому образу жизни и различным вариантам терапии, увеличивая риски осложнений и, как следствие, расходы системы здравоохранения. Актуальность вопросов скрининга и коррекции психоэмоциональных нарушений в практике врачей-терапевтов обусловлена, с одной стороны, высокой частотой встречаемости данных расстройств у пациентов с хроническими неинфекционными заболеваниями, ухудшением качества жизни и увеличением неблагоприятных исходов, а с другой – недостаточным уровнем осведомленности о возможностях коррекции психоэмоционального состояния пациентов с коморбидностью. Терапия психоэмоциональных нарушений включает как медикаментозные, так и немедикаментозные методы, однако эффективность такого лечения в отношении клинического течения и прогноза у пациентов с разными вариантами коморбидности не одинакова. В настоящем обозе представлены наиболее частые варианты коморбидности психоэмоциональных нарушений и соматических заболеваний в терапевтической практике. Рассмотрен вариант терапии психоэмоциональных нарушений у пациентов с различными вариантами коморбидности препаратами буспирон и тофизопам. Эффективность и безопасность тофизопама и буспирона изучены в многочисленных исследованиях у пациентов с хроническими заболеваниями и широким спектром тревожных расстройств, в том числе при длительном применении.

Psycho-emotional disorders such as depression and anxiety disorders are important modifiable risk factors for the development and complicated course of many common chronic non-communicable diseases. A particular feature of such comorbidity is the significant impact of psycho-emotional disorders on the motivation and adherence of patients to a healthy lifestyle and various therapy options, which increases the risks of complications and, as a consequence of this, the healthcare expenditures. The topicality of the issues of screening and management of psycho-emotional disorders in the general practitioner practice is caused, on the one hand, by high rate of these disorders in patients with chronic non-communicable diseases, deterioration in quality of life and an increase in adverse outcomes, and on the other hand, inadequate awareness of the possibilities to manage the psycho-emotional state of patients with comorbidities. The therapy for psycho-emotional disorders includes both drug and non-drug methods, however, the effectiveness of such therapy in relation to the clinical course and prognosis in patients with different comorbidities is not the same. This review presents the most common comorbidities of psycho-emotional disorders and somatic diseases in therapeutic practice. A buspirone and tofisopam therapy for psycho-emotional disorders in patients with various comorbidities was discussed. The efficacy and safety of tofisopam and buspirone have been studied in numerous studies in patients with chronic diseases and a wide range of anxiety disorders, including a long-term administration.

психоэмоциональные нарушениядепрессиятревожные расстройствахронические неинфекционные заболеваниякоморбидностьтофизопамбуспиронpsycho-emotional disordersdepressionanxiety disorderschronic non-communicable diseasescomorbiditytofisopambuspironeReferencesGBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/s01406736(18)32279-7.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/s01406736(18)32279-7.Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Александрова Л.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. https://doi.org/10.15829/1728-8800-2022-3235.Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M. et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3235.Драпкина О.М., Шишкова В.Н., Котова М.Б. Психоэмоциональные факторы риска хронических неинфекционных заболеваний в амбулаторной практике. Методические рекомендации для терапевтов. Кардио васкулярная терапия и профилактика. 2022;21(10):3438. https://doi.org/10.15829/1728-8800-2022-3438.Drapkina O.M., Shishkova V.M., Kotova M.B. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Guidelines for internists. Cardiovascular Therapy and Prevention. 2022;21(10):3438. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3438.Шишкова В.Н., Драницына Б.Г., Драпкина О.М. Алгоритмы ведения пациентов с тревогой в практике терапевта. Кардиоваскулярная терапия и профилактика. 2023;22(2):3526. https://doi.org/10.15829/1728-88002023-3526.Shishkova V.N., Dranitsyna Yu.G., Drapkina O.M. Algorithms for the management of patients with anxiety in the internist’s practice. Cardiovascular Therapy and Prevention. 2023;22(2):3526. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3526.Tong A., Wang X., Li F., Xu F., Li Q., Zhang F. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016;53(4):589–598. https://doi.org/10.1007/s00592-016-0845-1.Tong A., Wang X., Li F., Xu F., Li Q., Zhang F. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016;53(4):589–598. https://doi.org/10.1007/s00592-016-0845-1.Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77.Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77.Xiao T., Qiu H., Chen Y., Zhou X., Wu K., Ruan X., Wang N., Fu C. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89. https://doi.org/10.1186/s12888-018-1671-5.Xiao T., Qiu H., Chen Y., Zhou X., Wu K., Ruan X., Wang N., Fu C. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89. https://doi.org/10.1186/s12888-018-1671-5.Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409.Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409.Read J.R., Sharpe L., Modini M., Dear B.F. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36–46. https://doi.org/10.1016/j.jad.2017.06.009.Read J.R., Sharpe L., Modini M., Dear B.F. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36–46. https://doi.org/10.1016/j.jad.2017.06.009.Ronaldson A., Arias de la Torre J., Prina M., Armstrong D., Das-Munshi J., Hatch S. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021;8:100149. https://doi.org/10.1016/j.lanepe.2021.100149.Ronaldson A., Arias de la Torre J., Prina M., Armstrong D., Das-Munshi J., Hatch S. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021;8:100149. https://doi.org/10.1016/j.lanepe.2021.100149.Long J., Ouyang Y., Duan H., Xiang Z., Ma H., Ju M., Sun D. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1449–1464. https://doi.org/10.2147/COPD.S245842.Long J., Ouyang Y., Duan H., Xiang Z., Ma H., Ju M., Sun D. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1449–1464. https://doi.org/10.2147/COPD.S245842.Wen-Tao D., Xue-Xiu C., Zun-Jiang C., Wei C., Cheng-Feng P., Xing-Ken F. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022;13:817727. https://doi.org/10.3389/fgene.2022.817727.Wen-Tao D., Xue-Xiu C., Zun-Jiang C., Wei C., Cheng-Feng P., Xing-Ken F. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022;13:817727. https://doi.org/10.3389/fgene.2022.817727.Volpato E., Toniolo S., Pagnini F., Banfi P. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2001–2021. https://doi.org/10.2147/COPD.S313841.Volpato E., Toniolo S., Pagnini F., Banfi P. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2001–2021. https://doi.org/10.2147/COPD.S313841.Ställberg B., Janson C., Larsson K., Johansson G., Kostikas K., Gruenberger J.B. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. https://doi.org/10.1038/s41533-018-0101-y.Ställberg B., Janson C., Larsson K., Johansson G., Kostikas K., Gruenberger J.B. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. https://doi.org/10.1038/s41533-018-0101-y.Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD. 2019;16(5-6):406–417. https://doi.org/10.1080/15412555.2019.1679102.Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD. 2019;16(5-6):406–417. https://doi.org/10.1080/15412555.2019.1679102.Peyrot M., Rubin R.R., Lauritzen T., Snoek F.J., Matthews D.R., Skovlund S.E. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385. https://doi.org/10.1111/j.1464-5491.2005.01644.x.Peyrot M., Rubin R.R., Lauritzen T., Snoek F.J., Matthews D.R., Skovlund S.E. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385. https://doi.org/10.1111/j.1464-5491.2005.01644.x.Perrin N.E., Davies M.J., Robertson N., Snoek F.J., Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–1520. https://doi.org/10.1111/dme.13448.Perrin N.E., Davies M.J., Robertson N., Snoek F.J., Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–1520. https://doi.org/10.1111/dme.13448.Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383–2390. https://doi.org/10.2337/dc08-0985.Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383– 2390. https://doi.org/10.2337/dc08-0985.Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006;23(4):445–448. https://doi.org/10.1111/j.1464-5491.2006.01814.x.Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006;23(4):445–448. https://doi.org/10.1111/j.1464-5491.2006.01814.x.Huang C.J., Hsieh H.M., Tu H.P., Jiang H.J., Wang P.W., Lin C.H. Generalized anxiety disorder in type 2 diabetes mellitus: prevalence and clinical characteristics. Braz J Psychiatry. 2020;42(6):621–629. https://doi.org/10.1590/1516-4446-2019-0605.Huang C.J., Hsieh H.M., Tu H.P., Jiang H.J., Wang P.W., Lin C.H. Generalized anxiety disorder in type 2 diabetes mellitus: prevalence and clinical characteristics. Braz J Psychiatry. 2020;42(6):621–629. https://doi.org/10.1590/1516-4446-2019-0605.Deschênes S.S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). J Psychosom Res. 2015;78(2):137–142. https://doi.org/10.1016/j.jpsychores.2014.11.023.Deschênes S.S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). J Psychosom Res. 2015;78(2):137–142. https://doi.org/10.1016/j.jpsychores.2014.11.023.Ásbjörnsdóttir B., Vestgaard M., Do N.C., Ringholm L., Andersen L.L.T., Jensen D.M. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021;38(3):e14506. https://doi.org/10.1111/dme.14506.Ásbjörnsdóttir B., Vestgaard M., Do N.C., Ringholm L., Andersen L.L.T., Jensen D.M. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021;38(3):e14506. https://doi.org/10.1111/dme.14506.Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G., Roberts R., Nouwen A., Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. https://doi.org/10.1002/brb3.1981.Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G., Roberts R., Nouwen A., Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. https://doi.org/10.1002/brb3.1981.Winkley K., Upsher R., Stahl D., Pollard D., Kasera A., Brennan A. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232. https://doi.org/10.3310/hta24280.Winkley K., Upsher R., Stahl D., Pollard D., Kasera A., Brennan A. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232. https://doi.org/10.3310/hta24280.Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77.Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77.Stasiak C.E., Bazan K.S., Kuss R.S., Schuinski A.F., Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325–331. https://doi.org/10.5935/0101-2800.20140047.Stasiak C.E., Bazan K.S., Kuss R.S., Schuinski A.F., Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325–331. https://doi.org/10.5935/0101-2800.20140047.Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–3745. https://doi.org/10.1093/ndt/gfs295.Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–3745. https://doi.org/10.1093/ndt/gfs295.Chilcot J., Farrington K. The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease. J Am Soc Nephrol. 2019;30(7):1339–1340. https://doi.org/10.1681/ASN.2019030308.Chilcot J., Farrington K. The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease. J Am Soc Nephrol. 2019;30(7):1339–1340. https://doi.org/10.1681/ASN.2019030308.Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011;12(2):114–115. https://doi.org/10.1016/S1470-2045(11)70007-9.Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011;12(2):114–115. https://doi.org/10.1016/S1470-2045(11)70007-9.Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409.Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409.Wang Y.H., Li J.Q., Shi J.F., Que J.Y., Liu J.J., Lappin J.M. et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487–1499. https://doi.org/10.1038/s41380-019-0595-x.Wang Y.H., Li J.Q., Shi J.F., Que J.Y., Liu J.J., Lappin J.M. et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487–1499. https://doi.org/10.1038/s41380-019-0595-x.Celano C.M., Millstein R.A., Bedoya C.A., Healy B.C., Roest A.M., Huffman J.C. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105–1115. https://doi.org/10.1016/j.ahj.2015.09.013.Celano C.M., Millstein R.A., Bedoya C.A., Healy B.C., Roest A.M., Huffman J.C. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105–1115. https://doi.org/10.1016/j.ahj.2015.09.013.Шишкова В.Н., Устарбекова Д.Б., Шишков В.А., Имамгаязова К.Э., Капустина Л.А. Психоэмоциональные нарушения у пациентов с хронической сердечной недостаточностью. Терапия. 2022;(1):44–49. https://doi.org/10.18565/therapy.2022.1.44-49.Shishkova V.N., Ustarbekova D.B., Shishkov V.A., Imamgayazova K.E., Kapustina L.A. Psychoemotional disorders in patients with chronic heart failure. Therapy. 2022;(1):44–49. (In Russ.) https://doi.org/10.18565/therapy.2022.1.44-49.Шишкова В.Н. Простые и эффективные решения в коррекции тревоги и стресса. Медицинский совет. 2023;(3):161–167. https://doi.org/10.21518/ms2023-023.Shishkova V.N. Simple and effective solutions in the correction of anxiety and stress. Meditsinskiy Sovet. 2023;(3):161–167. (In Russ.) https://doi.org/10.21518/ms2023-023.Vaccarino V., Badimon L., Bremner J.D, Cenko E., Cubedo J., Dorobantu M. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696. https://doi.org/10.1093/eurheartj/ehy913.Vaccarino V., Badimon L., Bremner J.D, Cenko E., Cubedo J., Dorobantu M. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696. https://doi.org/10.1093/eurheartj/ehy913.Daskalopoulou M., George J., Walters K., Osborn D.P., Batty G.D., Stogiannis D. et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men. PLoS ONE. 2016;11(4):e0153838. https://doi.org/10.1371/journal.pone.0153838.Daskalopoulou M., George J., Walters K., Osborn D.P., Batty G.D., Stogiannis D. et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men. PLoS ONE. 2016;11(4):e0153838. https://doi.org/10.1371/journal.pone.0153838.Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139–150. https://doi.org/10.1016/j.neubiorev.2015.07.001.Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139–150. https://doi.org/10.1016/j.neubiorev.2015.07.001.Albus C., Waller C., Fritzsche K., Gunold H., Haass M., Hamann B. et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w.Albus C., Waller C., Fritzsche K., Gunold H., Haass M., Hamann B. et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w.Smyth A., O’Donnell M., Lamelas P., Teo K., Rangarajan S., Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–1067. https://doi.org/10.1161/CIRCULATIONAHA.116.023142.Smyth A., O’Donnell M., Lamelas P., Teo K., Rangarajan S., Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–1067. https://doi.org/10.1161/CIRCULATIONAHA.116.023142.Евстифеева С.Е., Шальнова С.А., Макарова Ю.К., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Ассоциируется ли уровень тревоги и депрессии в популяции со смертностью населения? По данным исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021;20(5):3009. https://doi.org/10.15829/1728-8800-2021-3009.Evstifeeva S.E., Shalnova S.A., Makarova Yu.K., Yarovaya E.B., Balanova Yu.A., Imaeva A.E. et al. Is the population level of anxiety and depression associated with mortality? Data from the ESSE-RF study. Cardiovascular Therapy and Prevention. 2021;20(5):3009. (In Russ.) https://doi.org/10.15829/17288800-2021-3009.Moise N., Khodneva Y., Jannat-Khah D.P., Richman J., Davidson K.W., Kronish I.M. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. https://doi.org/10.1136/bmjopen-2017-017385.Moise N., Khodneva Y., Jannat-Khah D.P., Richman J., Davidson K.W., Kronish I.M. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. https://doi.org/10.1136/bmjopen-2017-017385.Ye S., Muntner P., Shimbo D., Judd S.E., Richman J., Davidson K.W., Safford M.M. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61(6):622–630. https://doi.org/10.1016/j.jacc.2012.09.058.Ye S., Muntner P., Shimbo D., Judd S.E., Richman J., Davidson K.W., Safford M.M. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61(6):622–630. https://doi.org/10.1016/j.jacc.2012.09.058.Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439–448. https://doi.org/10.1016/j.jpsychores.2014.10.001.Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439–448. https://doi.org/10.1016/j.jpsychores.2014.10.001.Thompson D.R., Ski C.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013;20(6):916–917. https://doi.org/10.1177/2047487313494031.Thompson D.R., Ski C.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013;20(6):916–917. https://doi.org/10.1177/2047487313494031.Pizzi C., Rutjes A.W., Costa G.M., Fontana F., Mezzetti A., Manzoli L. Metaanalysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972–979. https://doi.org/10.1016/j.amjcard.2010.11.017.Pizzi C., Rutjes A.W., Costa G.M., Fontana F., Mezzetti A., Manzoli L. Metaanalysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972–979. https://doi.org/10.1016/j.amjcard.2010.11.017.He W., Zhou Y., Ma J., Wei B., Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919–926. https://doi.org/10.1007/s10741-019-09850-w.He W., Zhou Y., Ma J., Wei B., Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919–926. https://doi.org/10.1007/s10741-019-09850-w.Honkola J., Hookana E., Malinen S., Kaikkonen K.S., Junttila M.J., Isohanni M. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745–751. https://doi.org/10.1093/eurheartj/ehr368.Honkola J., Hookana E., Malinen S., Kaikkonen K.S., Junttila M.J., Isohanni M. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745–751. https://doi.org/10.1093/eurheartj/ehr368.Шишкова В.Н. Стратегия ведения и профилактики психоэмоциональных нарушений в практике терапевта. Медицинский совет. 2023;(6):76–82. https://doi.org/10.21518/ms2023-077.Shishkova V.N. Strategy for the management and prevention of psycho-emotional disorders in the GP’s practice. Meditsinskiy Sovet. 2023;(6):76–82. (In Russ.) https://doi.org/10.21518/ms2023-077.Стаценко М.Е., Говоруха О.А. Влияние Грандаксина на показатели качества жизни и темп реабилитации больных с сердечной недостаточностью, перенесших инфаркт миокарда. Лекарственный вестник. 2004;(2):23–28. Режим доступа: http://attic.volgmed.ru/publishing/lv/s/2004/2/lv-2004-2–023.pdf.Statsenko M.E., Govorukha O.A. The effect of grandaxin on the quality of life and the rate of rehabilitation of patients with heart failure who have suffered a myocardial infarction. Lekarstvennyi Vestnik. 2004;(2):23–28. (In Russ.) Available at: http://attic.volgmed.ru/publishing/lv/s/2004/2/lv-2004-2-023.pdf.Кулешова Э.В. Применение тофизопама (грандаксина) для лечения больных ишемической болезнью сердца. Клиническая фармакология и терапия. 2000;9(5):53–55. Режим доступа: https://medi.ru/info/8089/.Kuleshova E.V. The use of tofizopam (grandaxin) for the treatment of patients with coronary heart disease. Clinical Pharmacology and Therapy. 2000;9(5):53–55. (In Russ.) Available at: https://medi.ru/info/8089/.Левин О.С. Применение буспирона в клинической практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(4):83–87. https://doi.org/10.17116/jnevro20151154183-87.Levin O.S. The use of buspirone in clinical practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(4):83–87. (In Russ.) https://doi.org/10.17116/jnevro20151154183-87.Быков Ю.В., Беккер Р.А. Буспирон в практике врача-психиатра: только ли анксиолитик? Психиатрия и психофармакотерапия. 2017;19(5):32–52. Режим доступа: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-05-2017/buspiron_v_praktike_vracha_psikhiatra_tolko_li_anksiolitik/.Bykov Yu.V., Bekker R.A Buspiron in the practice of a psychiatrist: is it only an anxiolytic? Psikhiatriya i Psikhofarmakoterapiya. 2017;19(5):32–52. (In Russ.) Available at: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-05-2017/buspiron_v_praktike_vracha_psikhiatra_tolko_li_anksiolitik/.

The authors declare that there are no conflicts of interest present.